A note on improvement in Dermatology Life Quality Index (DLQI) among patients with hidradenitis suppurativa treated with adalimumab.

Related Articles

A note on improvement in Dermatology Life Quality Index (DLQI) among patients with hidradenitis suppurativa treated with adalimumab.

J Dermatolog Treat. 2018 Apr 19;:1-7

Authors: Thomsen SF

Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with profound negative impact on quality of life. Adalimumab (anti-TNF) is indicated for moderate-to-severe HS unresponsive to conventional therapy. Herein, studies of the change in Dermatology Life Quality Index (DLQI) among patients with HS treated with adalimumab are reviewed. The anticipated gain in DLQI is only modest in patients with HS treated with adalimumab, even in trials of high quality, and does not exceed the established minimal clinically important difference. Biologics targeting other inflammatory cytokines are warranted in the treatment of HS.

PMID: 29671663 [PubMed - as supplied by publisher]

https://ift.tt/2qNYvsi